GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » China Resources Boya Bio-pharmaceutical Group Co Ltd (SZSE:300294) » Definitions » Piotroski F-Score

China Resources Boya Bio-pharmaceutical Group Co (SZSE:300294) Piotroski F-Score : 5 (As of Apr. 26, 2024)


View and export this data going back to 2012. Start your Free Trial

What is China Resources Boya Bio-pharmaceutical Group Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

China Resources Boya Bio-pharmaceutical Group Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for China Resources Boya Bio-pharmaceutical Group Co's Piotroski F-Score or its related term are showing as below:

SZSE:300294' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 8
Current: 5

During the past 13 years, the highest Piotroski F-Score of China Resources Boya Bio-pharmaceutical Group Co was 8. The lowest was 3. And the median was 5.


China Resources Boya Bio-pharmaceutical Group Co Piotroski F-Score Historical Data

The historical data trend for China Resources Boya Bio-pharmaceutical Group Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resources Boya Bio-pharmaceutical Group Co Piotroski F-Score Chart

China Resources Boya Bio-pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 5.00 7.00 4.00 4.00

China Resources Boya Bio-pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 5.00 4.00 4.00 5.00

Competitive Comparison of China Resources Boya Bio-pharmaceutical Group Co's Piotroski F-Score

For the Biotechnology subindustry, China Resources Boya Bio-pharmaceutical Group Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Resources Boya Bio-pharmaceutical Group Co's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, China Resources Boya Bio-pharmaceutical Group Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where China Resources Boya Bio-pharmaceutical Group Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was 155.601 + 138.149 + -226.602 + 152.025 = ¥219 Mil.
Cash Flow from Operations was 170.505 + 132.522 + 116.021 + 123.872 = ¥543 Mil.
Revenue was 734.944 + 649.527 + 461.581 + 448.453 = ¥2,295 Mil.
Gross Profit was 386.936 + 327.26 + 303.055 + 303.995 = ¥1,321 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(8196.384 + 8167.575 + 8182.959 + 7828.9 + 7992.85) / 5 = ¥8073.7336 Mil.
Total Assets at the begining of this year (Mar23) was ¥8,196 Mil.
Long-Term Debt & Capital Lease Obligation was ¥24 Mil.
Total Current Assets was ¥6,613 Mil.
Total Current Liabilities was ¥470 Mil.
Net Income was 175.284 + 139.441 + 13.918 + 170.317 = ¥499 Mil.

Revenue was 744.082 + 684.026 + 675.957 + 805.928 = ¥2,910 Mil.
Gross Profit was 406.925 + 382.548 + 361.022 + 381.867 = ¥1,532 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(7679.391 + 7850.81 + 7979.553 + 8033.175 + 8196.384) / 5 = ¥7947.8626 Mil.
Total Assets at the begining of last year (Mar22) was ¥7,679 Mil.
Long-Term Debt & Capital Lease Obligation was ¥10 Mil.
Total Current Assets was ¥6,239 Mil.
Total Current Liabilities was ¥730 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

China Resources Boya Bio-pharmaceutical Group Co's current Net Income (TTM) was 219. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

China Resources Boya Bio-pharmaceutical Group Co's current Cash Flow from Operations (TTM) was 543. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=219.173/8196.384
=0.02674021

ROA (Last Year)=Net Income/Total Assets (Mar22)
=498.96/7679.391
=0.0649739

China Resources Boya Bio-pharmaceutical Group Co's return on assets of this year was 0.02674021. China Resources Boya Bio-pharmaceutical Group Co's return on assets of last year was 0.0649739. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

China Resources Boya Bio-pharmaceutical Group Co's current Net Income (TTM) was 219. China Resources Boya Bio-pharmaceutical Group Co's current Cash Flow from Operations (TTM) was 543. ==> 543 > 219 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=23.549/8073.7336
=0.00291674

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=9.757/7947.8626
=0.00122763

China Resources Boya Bio-pharmaceutical Group Co's gearing of this year was 0.00291674. China Resources Boya Bio-pharmaceutical Group Co's gearing of last year was 0.00122763. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=6612.77/469.707
=14.0785

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=6239.082/729.98
=8.54692183

China Resources Boya Bio-pharmaceutical Group Co's current ratio of this year was 14.0785. China Resources Boya Bio-pharmaceutical Group Co's current ratio of last year was 8.54692183. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

China Resources Boya Bio-pharmaceutical Group Co's number of shares in issue this year was 506.75. China Resources Boya Bio-pharmaceutical Group Co's number of shares in issue last year was 500.934. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1321.246/2294.505
=0.57583052

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1532.362/2909.993
=0.52658615

China Resources Boya Bio-pharmaceutical Group Co's gross margin of this year was 0.57583052. China Resources Boya Bio-pharmaceutical Group Co's gross margin of last year was 0.52658615. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=2294.505/8196.384
=0.27994113

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=2909.993/7679.391
=0.37893539

China Resources Boya Bio-pharmaceutical Group Co's asset turnover of this year was 0.27994113. China Resources Boya Bio-pharmaceutical Group Co's asset turnover of last year was 0.37893539. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+0+1+0+1+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

China Resources Boya Bio-pharmaceutical Group Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

China Resources Boya Bio-pharmaceutical Group Co  (SZSE:300294) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


China Resources Boya Bio-pharmaceutical Group Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of China Resources Boya Bio-pharmaceutical Group Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


China Resources Boya Bio-pharmaceutical Group Co (SZSE:300294) Business Description

Traded in Other Exchanges
N/A
Address
Number 333, Huiquan Road, High-tech Industrial Park, Jiangxi Province, Fuzhou, CHN, 344000
China Resources Boya Bio-pharmaceutical Group Co Ltd is a China-based medical industry group that integrates biochemical drugs, chemical drugs, and active pharmaceutical ingredients. It is engaged in the provision of medical and health products and services. The product categories of the company include blood products, biochemical drugs, chemical medicines and others. Some of the company's blood products include human albumin, rabies immunoglobulin, intravenous human immunoglobulin and human fibrinogen.

China Resources Boya Bio-pharmaceutical Group Co (SZSE:300294) Headlines

No Headlines